source
- Nearly one in five patients stopped Boehringer's obesity shot in Phase 3 trial because of side effectsBoehringer Ingelheim’s obesity drug survodutide, licensed from Zealand Pharma, was evaluated in the Phase 3 SYNCHRONIZE-1 study. The trial reported that 19% of participants discontinued the treatm…
- Pfizer's Berobenatide GLP-1 injection shows efficacy in obesity and diabetes in early dataPfizer presented early data on its long-acting GLP-1 injection, Berobenatide, at a conference on June 6, 2026. The results indicated the drug was effective in patients who have both obesity and d…